<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of disorders characterized by cytopenias, with a propensity for evolution into <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This transformation is driven by genomic instability, but mechanisms remain unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Telomere dysfunction might generate genomic instability leading to cytopenias and disease progression </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: We undertook a pilot study of 94 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (56 patients) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (38 patients) </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cohort consisted of refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (32 cases), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (12 cases), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>)1 (8 cases), <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> (1 case), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (2 cases), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with isolated del(5q) (1 case) </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cohort was composed of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4 (12 cases), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M2 (10 cases), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M5 (5 cases), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M0 (5 cases), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M1 (2 cases), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M4eo (1 case), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with multidysplasia-related changes (1 case) </plain></SENT>
<SENT sid="6" pm="."><plain>Three-dimensional quantitative FISH of telomeres was carried out on nuclei from bone marrow samples and analyzed using TeloView </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: We defined three-dimensional nuclear telomeric profiles on the basis of telomere numbers, telomeric aggregates, telomere signal intensities, nuclear volumes, and nuclear telomere distribution </plain></SENT>
<SENT sid="8" pm="."><plain>Using these parameters, we blindly subdivided the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients into nine subgroups and the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients into six subgroups </plain></SENT>
<SENT sid="9" pm="."><plain>Each of the parameters showed significant differences between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Combining <z:hpo ids='HP_0000001'>all</z:hpo> parameters revealed significant differences between <z:hpo ids='HP_0000001'>all</z:hpo> subgroups </plain></SENT>
<SENT sid="11" pm="."><plain>Three-dimensional telomeric profiles are linked to the evolution of telomere dysfunction, defining a model of progression from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Our results show distinct three-dimensional telomeric profiles specific to patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> that help subgroup patients based on the severity of telomere dysfunction highlighted in the profiles </plain></SENT>
</text></document>